Antibody-drug conjugates for pediatric osteosarcoma therapy
Official title: Project 3: Development of Novel Antibody Drug Conjugates for the Treatment of Osteosarcoma
Funded at University of Tx Md Anderson Can Ctr · NIH-11397833 · Data updated 2026-11-12
A grant to develop targeted antibody-drug conjugates aimed at treating pediatric osteosarcoma by delivering cancer drugs directly to tumor cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 19, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $468,387 |
| NIH project number | 5P50CA302482-02 |
| Project ID | NIH-11397833 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are children and young adults with osteosarcoma whose tumors express targetable surface proteins and who may benefit from antibody-drug conjugate therapy.
✕Less likely to help
Patients whose tumors do not express the target proteins or cannot tolerate antibody-drug conjugates may not benefit.
What this research studies
This project focuses on creating antibody-drug conjugates that target proteins on osteosarcoma cells in children and young adults. Researchers will translate these therapies toward clinical use, aiming to minimize damage to healthy tissue. The work includes identifying surface proteins, testing payloads, and developing biomarkers from blood to predict who will respond best to treatment.
Why it matters
Potential benefit: If successful, patients with osteosarcoma could have more effective, less toxic treatment options and better chances of long-term survival.
How similar studies have gone: Other cancers have approved antibody-drug conjugates, but this approach for osteosarcoma is translational and building on emerging targets and biomarkers.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Gorlick, Richard G. — University of Tx Md Anderson Can Ctr
- Study coordinator: Gorlick, Richard G.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Histotripsy + immune boost to fight osteosarcoma
A new treatment idea combines a precise non-surgical ultrasound method with an immune-boosting compound to help fight bone cancer in people and dogs.
-
Genomically guided drug testing for osteosarcoma in patient-derived models
A precision approach tests new drugs on osteosarcoma models created from patients to find promising treatments for kids and teens.
-
New ways to stop osteosarcoma from spreading
Researchers are testing new approaches to block how osteosarcoma spreads, with the aim of improving survival for children and adults with metastatic disease.
-
Targeting OST Redundancy to Treat Osteosarcoma
A study in people with advanced bone cancer to see if new OST-targeting drugs can slow or stop tumor growth.
-
Focal Adhesion Kinase inhibitor to block osteosarcoma spread to the lungs
A cancer treatment plan tests whether blocking a specific cell signal can stop osteosarcoma from growing and spreading to the lungs in kids and young people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.